Ferring Pharmaceuticals' 1st in Class C.diff Treatment, Rebyota, Experiences a Positive Early Launch Ahead of Potential Competition, According to Spherix Global Insights
EXTON, Pa., March 17, 2023 /PRNewswire/ -- When the FDA approved Rebyota, a new class of Clostridioides Difficile (C.diff) treatment, Ferring Pharmaceuticals ushered in the first significant breakthrough doctors treating the disease have seen in years. Rebyota falls in the class of therapy known as Fecal Microbiota Transplant, or FMT, a therapy over 60% of treating gastroenterologists believe will dramatically change the paradigm of C.diff treatment in the next five years, according to research from Spherix Global Insights Market Dynamix™ Clostridioides Difficile (US) service.
- At least two additional FMT treatments are in development for C.diff, including Aimmune/Seres' SER-109 and Vedanta Biosciences' VE303.
- With a first to market advantage, Ferring's Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch.
- As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
- A few headwinds Ferring may be facing with Rebyota include its mode of administration, and storage and handling requirements.